Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies


Study Number
721020
Phase
I
Age Group
Adult
Purpose

This is a phase 1, open-label, multicenter dose-escalation study to determine the RP2D of CI 8993 for administration to patients with relapsed/refractory solid tumors by evaluating the safety and tolerability and characterizing the PK, PD, and anti cancer activity of CI-8993 in this population.

Full Title

CI-8993-101 Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients with Advanced Solid Tumor Malignancies

ClinicalTrials.Gov ID
NCT04475523

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.